SNDX
insider transactionsSyndax Pharmaceuticals Inc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-327.3K
0 buy · 327.3K sell
Net value · 365d
-$5.5M
$0 in · $5.5M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
14
0 buy · 327.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Exercise·M
Head of R&D, CMO · 10b5-1
$0
53.8K sh · 2 lots
Own New
-
Sell·S
Head of R&D, CMO · 10b5-1
$1.2M
65.5K sh · $18.07 avg · 2 lots
Own -52%
-
Exercise·M
Head of R&D, CMO · 10b5-1
$742.8K
53.8K sh · $13.82 avg · 2 lots
Own +140%
-
Sell·S
Chief Executive Officer
$130.0K
6.8K sh · $18.99
Own -1%
-
Sell·S
Goldan Keith A. KEY
Chief Financial Officer
$22.4K
1.2K sh · $18.99
Own -1%
-
Sell·S
Chief Executive Officer
$360.9K
17.2K sh · $21.03
Own -3%
-
Sell·S
Goldan Keith A. KEY
Chief Financial Officer
$71.7K
3.4K sh · $21.03
Own -2%
-
Sell·S
Chief Executive Officer
$152.8K
7.4K sh · $20.62
Own -1%
-
Sell·S
Goldan Keith A. KEY
Chief Financial Officer
$42.9K
2.1K sh · $20.62
Own -1%
-
Grant·A
Director
$0
24.0K sh
Own +24%
-
Grant·A
Director
$0
48.0K sh
Own +25%
-
Grant·A
Chief Executive Officer
$9.0M
440.0K sh · $20.43
Own New
-
Grant·A
Chief Executive Officer
$0
217.6K sh · 2 lots
Own +73%
-
Grant·A
Head of R&D, CMO
$3.0M
144.7K sh · $20.43
Own New
-
Grant·A
Head of R&D, CMO
$0
60.0K sh · 2 lots
Own New
-
Grant·A
Director
$0
24.0K sh
Own +27%
-
Grant·A
Goldan Keith A. KEY
Chief Financial Officer
$2.4M
118.0K sh · $20.43
Own New
-
Grant·A
Goldan Keith A. KEY
Chief Financial Officer
$0
52.2K sh · 2 lots
Own +83%
-
Grant·A
Director
$0
24.0K sh
Own +96%
-
Grant·A
Director
$0
24.0K sh
Own +27%
-
Grant·A
Director
$0
24.0K sh
Own +30%
-
Other·J
Goldan Keith A. KEY
Chief Financial Officer
$10.3K
1.2K sh · $8.48
-
Other·G
Goldan Keith A. KEY
Chief Financial Officer
$0
1.2K sh
Own -1%
-
Exercise·M
Chief Executive Officer · 10b5-1
$0
157.3K sh
Own New
-
Exercise·M
Chief Executive Officer · 10b5-1
$1.7M
157.3K sh · $10.90
Own +53%
-
Sell·S
Chief Executive Officer · 10b5-1
$2.6M
157.3K sh · $16.41
Own -34%
-
Exercise·M
Director · 10b5-1
$0
57.6K sh · 4 lots
Own New
-
Exercise·M
Director · 10b5-1
$414.7K
57.6K sh · $7.20 avg · 3 lots
Own +38%
-
Sell·S
Director · 10b5-1
$874.9K
57.6K sh · $15.19 avg · 3 lots
Own -23%
-
Other·J
Goldan Keith A. KEY
Chief Financial Officer
$10.3K
1.2K sh · $8.43
-
Sell·S
Goldan Keith A. KEY
Chief Financial Officer
$12.0K
1.3K sh · $9.29
Own -1%
-
Sell·S
Chief Executive Officer
$70.0K
7.5K sh · $9.29
Own -2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas A.J. 10b5-1 | Exercise M | 53.8K2 lots | $0 |
| Jun 12, 2026 | Botwood Nicholas A.J. 10b5-1 | Sell S | 65.5K2 lots | $1.2M |
| Jun 12, 2026 | Botwood Nicholas A.J. 10b5-1 | Exercise M | 53.8K2 lots | $742.8K |
| Jun 1, 2026 | Metzger Michael A KEY | Sell S | 6.8K | $130.0K |
| Jun 1, 2026 | Goldan Keith A. KEY | Sell S | 1.2K | $22.4K |
| Feb 9, 2026 | Metzger Michael A KEY | Sell S | 17.2K | $360.9K |
| Feb 9, 2026 | Goldan Keith A. KEY | Sell S | 3.4K | $71.7K |
| Feb 6, 2026 | Metzger Michael A KEY | Sell S | 7.4K | $152.8K |
| Feb 6, 2026 | Goldan Keith A. KEY | Sell S | 2.1K | $42.9K |
| Feb 4, 2026 | Katkin Keith | Grant A | 24.0K | $0 |
| Feb 4, 2026 | Podlesak Dennis | Grant A | 48.0K | $0 |
| Feb 4, 2026 | Metzger Michael A KEY | Grant A | 440.0K | $9.0M |
| Feb 4, 2026 | Metzger Michael A KEY | Grant A | 217.6K2 lots | $0 |
| Feb 4, 2026 | Botwood Nicholas A.J. | Grant A | 144.7K | $3.0M |
| Feb 4, 2026 | Botwood Nicholas A.J. | Grant A | 60.0K2 lots | $0 |
| Feb 4, 2026 | Jarrett Jennifer | Grant A | 24.0K | $0 |
| Feb 4, 2026 | Goldan Keith A. KEY | Grant A | 118.0K | $2.4M |
| Feb 4, 2026 | Goldan Keith A. KEY | Grant A | 52.2K2 lots | $0 |
| Feb 4, 2026 | Rizo Aleksandra | Grant A | 24.0K | $0 |
| Feb 4, 2026 | Legault Pierre | Grant A | 24.0K | $0 |
| Feb 4, 2026 | Huber Martin H. Jr. | Grant A | 24.0K | $0 |
| Jan 30, 2026 | Goldan Keith A. KEY | Other J | 1.2K | $10.3K |
| Dec 1, 2025 | Goldan Keith A. KEY | Other G | 1.2K | $0 |
| Sep 8, 2025 | Metzger Michael A KEY 10b5-1 | Exercise M | 157.3K | $0 |
| Sep 8, 2025 | Metzger Michael A KEY 10b5-1 | Exercise M | 157.3K | $1.7M |
| Sep 8, 2025 | Metzger Michael A KEY 10b5-1 | Sell S | 157.3K | $2.6M |
| Aug 18, 2025 | Podlesak Dennis 10b5-1 | Exercise M | 57.6K4 lots | $0 |
| Aug 18, 2025 | Podlesak Dennis 10b5-1 | Exercise M | 57.6K3 lots | $414.7K |
| Aug 18, 2025 | Podlesak Dennis 10b5-1 | Sell S | 57.6K3 lots | $874.9K |
| Jul 31, 2025 | Goldan Keith A. KEY | Other J | 1.2K | $10.3K |
| Jul 16, 2025 | Goldan Keith A. KEY | Sell S | 1.3K | $12.0K |
| Jul 16, 2025 | Metzger Michael A KEY | Sell S | 7.5K | $70.0K |
Buy Sell Non-market (grant · exercise · gift)
About SNDX insider trading
This page tracks insider transactions for Syndax Pharmaceuticals Inc (SNDX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.